Targeted and efficient delivery of rifampicin to macrophages involved in non-tuberculous mycobacterial infection <i>via</i> mannosylated solid lipid nanoparticles

, a causative agent of non-tuberculous lung disease. Therefore, this study demonstrated that mannose receptor-targeted rifampicin delivery through solid lipid nanoparticles can be effectively applied to the treatment of non-tuberculous lung disease. Moreover, Man-RIF SLNs could also be used for the targeted delivery of drugs to several types of carcinoma cells or immune cells, as well as to treat lung diseases.